The European system of approval of new medicines comprises an European Union (EU)-wide authorisation procedure (the so called centralised pro- cedure) alongside national procedures based on different EU Member States working together and recognizing each other’s evaluations (the so-called decentralised and mutual recognition procedures). It is a system that has evolved over the past half-century